Prognostic Factors for Overall Survival of Patients with Prostate Cancer in Kyadondo County, Uganda

Yahaya, James J.; Okecha, Tonny; Odida, Michael; Wabinga, Henry

doi:10.1155/2020/8517130

Cited by 8 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bello et al published a small study evaluating factors associated with OS among 48 Nigerian men with metastatic castrate resistant PCa 33 . In a study including both patients with localized and metastatic PCa from Uganda ( n = 36 patients with stage IV disease), Yahaya et al 34 . found that Gleason score and LVI were independent predictors of survival.…”

Section: Discussionmentioning

confidence: 99%

Biochemical progression free and overall survival among Black men with stage IV prostate cancer in South Africa: Results from a prospective cohort study

Pumpalova,

Ramakrishnan,

May

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

BackgroundMen of African descent are disproportionately affected by prostate cancer (PCa), and many have metastatic disease at presentation. In South Africa (SA), androgen deprivation therapy (ADT) is the first‐line treatment for stage IV PCa.ObjectiveTo identify predictors of overall survival (OS) in Black South African men with stage IV PCa treated with ADT.Design, Setting, and ParticipantsMen diagnosed with prostate cancer (3/22/2016–10/30/2020) at Chris Hani Baragwanath Academic Hospital in Soweto, Johannesburg, were recruited for the Men of African Descent with Cancer of the Prostate study. We included men with newly diagnosed stage IV PCa treated with ADT who had a prostate‐specific antigen (PSA) level drawn prior to initiation of ADT and had ≥1 PSA drawn ≥12 weeks after ADT start.Outcomes Measures and Statistical AnalysisWe used Kaplan–Meier statistics to estimate OS and Cox regression models to identify predictors of OS.Results and LimitationsOf the 1097 men diagnosed with prostate cancer, we included 153 men with stage IV PCa who received ADT and met PSA requirements. The median age was 68.0 years (interquartile range 64–73 years). Median OS from time of ADT initiation was 3.39 years (95% confidence interval (CI): 3.14%–noncalculable), while biochemical progression‐free survival was 2.36 years (95% CI: 2.03%–3.73%). Biochemical progression (HR 3.52, 95% CI: 1.85%–6.70%), PSA nadir level >4 ng/mL (HR 3.77, 95% CI: 1.86%–7.62%), alkaline phosphatase level at diagnosis >150 IU/dL (HR 3.09, 95% CI: 1.64%–5.83%), and hemoglobin at diagnosis <13.5 g/dL (HR 2.90, 95% CI: 1.28%–6.56%) were associated with worse OS.ConclusionsIn this study, we identified factors associated with poor OS among Black South African men with stage IV PCa treated with ADT. These factors may be useful in identifying patients for upfront treatment escalation, including the use of docetaxel chemotherapy or escalation of therapy at the time of biochemical progression.Patient SummaryIn this study, we found that high alkaline phosphatase level, anemia at diagnosis, and high PSA nadir after initiation of androgen deprivation therapy are associated with worse overall survival among Black South African men treated with androgen deprivation therapy for metastatic prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Biochemical progression free and overall survival among Black men with stage IV prostate cancer in South Africa: Results from a prospective cohort study

Pumpalova,

Ramakrishnan,

May

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…This observation reflects the spread of PCa from a distance in most of our patients. A Ugandan study reported a 3-year overall survival rate of 67.6% with a median survival of 36.5 months [ 29 ]. These authors had found that Gleason score, clinical stage, and lymphovascular invasion can independently predict the overall survival of the patients with PCa [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

“…A Ugandan study reported a 3-year overall survival rate of 67.6% with a median survival of 36.5 months [ 29 ]. These authors had found that Gleason score, clinical stage, and lymphovascular invasion can independently predict the overall survival of the patients with PCa [ 29 ]. Ndoye et al [ 8 ] emphasize not only the delay in diagnosis observed in most sub-Saharan countries but also the lack of policy of channeling these patients suffering from PCa to a center applying the recommendations of learned societies for a codification of management.…”

Section: Discussionmentioning

confidence: 99%

Clinical, Histopathological, and Prognostic Characteristics of Patients with Prostate Cancer in Lubumbashi, Democratic Republic of Congo

et al. 2020

View full text Add to dashboard Cite

Introduction. Prostate cancer is currently a public health problem with a frequency that varies from country to country. This study aims to describe the epidemiological, clinical, and histopathological and outcome features of prostate cancer in Lubumbashi in the Democratic Republic of Congo. Materials and Methods. This was a descriptive longitudinal study of patients diagnosed with prostate cancer at the University Clinics of Lubumbashi. The study period was 3 years (2017 to 2019). Parameters studied were age and clinical, biological (PSA level, prostatic specific antigen), histopathological, and outcome features. Results. The mean age of patients was 68.7 years (range: 47 and 90 years). The 60 to 69 age group was the most affected (43.18%). Elderly subjects (≥60 years old) represented 89.77% of the cases (n = 79). Voiding disorders were the main reason for consultation in 55.68% of the cases. The mean PSA level was 133.7 ng/ml (range: 4 and 1564.5 ng/ml) at diagnosis and 125.4 ng/ml after 3 months of follow-up (range: 0.16 and 1782.1 ng/ml). Adenocarcinoma was the predominant histological type (100%). In prognosis, 31.82% of patients had a Gleason score greater than 7 and 59.10% had a high risk at the D’Amico risk classification for Prostate Cancer. Hormone therapy was administered alone in 75% of the cases and in combination with pulpectomy in 13.64% of the cases. The 3-year overall survival was 56.82%. Conclusion. Prostate cancer is frequent and has a poor outcome in our country. The establishment of an individual screening policy would be an undeniable advantage in improving the prognosis.

show abstract

“…Yahaya et al and Okuku et al in two different studies reported 73.1% and 54.8% of patients with PCa in Uganda had Gleason score ≥ 8 [13,14]. In other two studies done in Uganda by Yahaya, it was reported that 44.6% and 55.9% of the patients with PCa had Gleason score ≥ 8 [15,16]. In all the four studies, none of them involved determining of expression of either BRCA1 or BRCA2 protein.…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemical expression of BRCA1 and BRCA2 in a cohort of Ugandan men with prostate cancer: an analytical cross-sectional study

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Mutation of the tumour suppressor genes BRCA1 and BRCA2 is thought to cause early development of prostate cancer which has poor prognosis. The purpose of this study was to determine the expression of BRCA1/2 and correlate it with clinicopathological factors for patients with prostate cancer in uganda. Methods Retrospectively, we used immunohistochemistry to evaluate the expression of BRCA1/2 antibodies in tissue blocks of 188 patients with prostate cancer who were diagnosed between January 2005 and December 2014 in the Department of Pathology, Makerere College of Health Sciences. The Chi-Square test was used to determine the association of the categorical variables, whereas t-test was used to compare groups of mean of the variables in the study. Results Expression of BRCA1 and BRCA2 was found in 26.1% and 22.9% cases, respectively. Co-expression of BRCA1 and BRCA2 was found in only 7.4%. Gleason score was associated with expression of BRCA1 and BRCA2 (P = 0.013, P = 0.041, respectively). Age was not associated with BRCA1 and BRCA2 expression; P = 0.543, P = 0.091, respectively. Likewise, PSA was not associated with BRCA1 and BRCA2 expression; P = 0.446, P = 0.399, respectively. Conclusion BRCA1 and BRCA2 proteins in this study were expressed more in cases with poorly differentiated prostate cancer than in cases with either well or moderately differentiated prostate cancer. Co-expression of BRCA1 and BRCA2 proteins in the same patient in our study was 3 times less than either BRCA1 or BRCA2 alone.

show abstract

Prognostic Factors for Overall Survival of Patients with Prostate Cancer in Kyadondo County, Uganda

Cited by 8 publications

References 35 publications

Biochemical progression free and overall survival among Black men with stage IV prostate cancer in South Africa: Results from a prospective cohort study

Biochemical progression free and overall survival among Black men with stage IV prostate cancer in South Africa: Results from a prospective cohort study

Clinical, Histopathological, and Prognostic Characteristics of Patients with Prostate Cancer in Lubumbashi, Democratic Republic of Congo

Immunohistochemical expression of BRCA1 and BRCA2 in a cohort of Ugandan men with prostate cancer: an analytical cross-sectional study

Contact Info

Product

Resources

About